Results 21 to 30 of about 100,641 (375)
Mechanisms of peripheral levodopa resistance in Parkinson’s disease
npj Parkinson's Disease, 2022 Parkinson’s disease (PD) is an increasingly common neurodegenerative condition. The disease has a significant negative impact on quality of life, but a personalized management approach can help reduce disability. Pharmacotherapy with levodopa remains the
Milan Beckers, B. Bloem, M. Verbeek
semanticscholar +1 more source
Cells, 2021 Dyskinesias are characterized by abnormal repetitive involuntary movements due to dysfunctional neuronal activity. Although levodopa-induced dyskinesia, characterized by tic-like abnormal involuntary movements, has no clinical treatment for Parkinson’s ...
Luca Pagliaroli +9 more
doaj +1 more source
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide
Movement Disorders Clinical Practice, 2020 There has been a steadily growing armamentarium of drugs for the symptomatic treatment of Parkinson’s disease (PD). Consequently, as various various pharmaceutical agents are used, it has become more difficult to perform and compare clinical trials with ...
Sebastian Schade +2 more
semanticscholar +1 more source
Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson's disease.
PLoS ONE, 2020 A higher levodopa dose is a strong risk factor for levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). However, levodopa dose can change during long-term medication.
Jin Yong Hong +6 more
doaj +1 more source
Advances in Nutrition, 2021 Although levodopa remains the most effective drug for symptomatic management of Parkinson's Disease (PD), treatment during advanced disease stages may raise unpredictable motor fluctuations and other complications.
Jikke T Boelens Keun +3 more
semanticscholar +1 more source
Levodopa-responsive chorea: A review
Annals of Indian Academy of Neurology, 2020 Background: Chorea is one of the disabling movement disorders, and the number of drugs which can treat this disorder effectively is limited. Tetrabenazine and deutetrabenazine are the two drugs approved by the US-FDA for the treatment of chorea ...
Mark Farrenburg, Harsh V Gupta
doaj +1 more source
npj Parkinson's Disease, 2023 The relationship between dopaminergic treatment and freezing of gait (FOG) in Parkinson’s disease (PD) is complex: levodopa is the most effective symptomatic treatment for FOG, but long-term pulsatile levodopa treatment has also been linked to an ...
Jamie A. F. Jansen +6 more
doaj +1 more source
An updated calculator for determining levodopa-equivalent dose
Neurological Research and Practice, 2021 Calculation of levodopa-equivalent dose in Parkinson’s disease has become common in research, but is also a useful tool in clinical practice, especially when initiating device-aided treatments (deep brain stimulation, apomorphine and levodopa infusions).
D. Nyholm, W. Jost
semanticscholar +1 more source
Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease [PDF]
, 2003 Background: Although the short-term benefits of bilateral stimulation of the subthalamic nucleus in patients with advanced Parkinson's disease have been well documented, the long-term outcomes of the procedure are unknown. Methods: We conducted a five-
Krack, P. +11 more
core +4 more sources
Natural history of motor symptoms in Parkinson’s disease and the long-duration response to levodopa
Brain : a journal of neurology, 2020 See Poewe and Espay (doi:10.1093/brain/awaa226) for a scientific commentary on this article. Cilia et al. describe the natural course of motor symptoms in drug-naïve patients with Parkinson’s disease and the effects of long-term levodopa on motor ...
R. Cilia +11 more
semanticscholar +1 more source